37 results on '"Willekens, Christophe"'
Search Results
2. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
3. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia
4. Reduced Venetoclax Exposition to Seven Days of Azacitidine Is Efficient in Treatment-Naïve Patients with Acute Myeloid Leukemia
5. JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation
6. SRSF2-P95Hdelays Myelofibrosis Development through Altered JAK/STAT Signaling in JAK2-V617F Megakaryocytes
7. Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia
8. Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers
9. ATG2B/Gskip in De Novo Acute Myeloid Leukemia (AML): High Prevalence of Germline Predisposition in French West Indies and Potential Role of Overexpression in Acquired AML
10. Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2 Inhibitor Enasidenib in Acute Myeloid Leukemia
11. Repetitive Low-Dose Radiation Therapies As an Alternative Option for Indolent Non-Hodgkin Lymphoma
12. Synthetic Lethal Interactions of MDS-Associated Spliceosomal Gene Mutations Identifies the Basis for Their Mutual Exclusivity
13. Safety, Phamacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study
14. Survival Improvement in Therapy Related Myeloid Neosplasm ? a Single Center Analysis of 428 Patients
15. 1-Year Data Analysis from a Cancer Center Molecular Tumor Board Dedicated to Clonal Hematopoiesis
16. Serum 2-Hydroxyglutarate Level Can Predict IDH2 Mutation in Myeloid Sarcoma
17. Serum 2-Hydroxyglutarate Allows Early Prediction of Response during Induction Chemotherapy in Acute Myeloid Leukemia with IDH Mutation
18. A Series of 116 Therapy-Related Myeloid Neoplasms (t-MN) Patients from 2 French Comprehensive Cancer Centers
19. The Impact of Risk-Adapted Treatment Strategy on Outcome of Patients with Acute Myeloid Leukemia Aged ≥ 60 Years after Allogeneic Stem Cell Transplantation
20. Efficacy of 5-Azacitidine on IDH1/2 Acute Myeloid Leukemia/Myelodysplastic Syndromes and Correlation with 2-Hydroxyglutarate Production
21. AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model
22. Concurrent Radiation and ESHAP Regimen in Localized Extranodal NK/T-Cell Lymphoma Nasal Type, Phase II French Study
23. A Simple Scoring System for Identifying Relapsed/Refractory Lymphoma Patients Prematurely Withdrawn from Phase I Trials: The Gustave Roussy Experience
24. Inherited transmission of the CSF3RT618I mutational hotspot in familial chronic neutrophilic leukemia
25. Treatment With Decitabine (DAC) After Azacitidine (AZA) Failure In High Risk Myelodysplastic Syndrome (MDS) and Advanced Chronic Myelomonocytic Leukemia (CMML)
26. AML At First Relapse: A Real Life Picture
27. Bone marrow necrosis: a culture medium for bacteria
28. Enasidenib in mutant IDH2relapsed or refractory acute myeloid leukemia
29. Rituximab-Cyclophosphamide-Dexamethasone (RCD) Combination In the Management of Autoimmune Cytopenias Associated with Chronic Lymphocytic Leukaemia
30. Prognostic Value of PINI in Elderly Patients with Multiple Myeloma (MM).
31. Wireless Video-Capsule Endoscopy Is a More Sensitive Investigative Method Than Gastro-Intestinal Endoscopy and Biopsies for the Diagnosis of Acute GI-Gvhd.
32. Efficacy of Imatinib Mesylate in the Treatment of Refractory Sclerodermatous Chronic Graft-Versus-Host Disease.
33. ATG2B/Gskipin De NovoAcute Myeloid Leukemia (AML): High Prevalence of Germline Predisposition in French West Indies and Potential Role of Overexpression in Acquired AML
34. Dose-Adjusted Rituximab Mini-CYVE (CYtarabine bolus, VEpeside and dexamethasone) for Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Not Eligible for High Dose Therapy
35. Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2Inhibitor Enasidenib in Acute Myeloid Leukemia
36. Serum 2-Hydroxyglutarate Level Can Predict IDH2Mutation in Myeloid Sarcoma
37. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.